<scp>In‐vivo</scp> and ex‐vivo tests for culprit drugs identification in severe cutaneous adverse drugs reactions-Reference-Cited by-同舟云学术

In‐vivo and ex‐vivo tests for culprit drugs identification in severe cutaneous adverse drugs reactions

Published:2024-04-11 Issue: Volume: Page:
ISSN:0385-2407
Container-title:The Journal of Dermatology
language:en
Short-container-title:The Journal of Dermatology

Author:

Sittiwattanawong P.¹,Kantikosum K.¹,Charoenchaipiyakul K.¹^ORCID,Pootongkam S.¹,Asawanonda P.¹^ORCID,Kerr S. J.²,Thantiworasit P.³,Sodsai P.⁴,Hirankarn N.⁴,Klaewsongkram J.³,Rerknimitr P.¹^ORCID

Affiliation:

1. Division of Dermatology, Department of Medicine, Faculty of Medicine, Center of Excellence for Skin and Allergy Research Chulalongkorn University Bangkok Thailand

2. Center for Excellence in Biostatistics, Faculty of Medicine Chulalongkorn University Bangkok Thailand

3. Division of Allergy and Clinical Immunology, Department of Medicine, Faculty of Medicine, Center of Excellence for Skin and Allergy Research Chulalongkorn University Bangkok Thailand

4. Division of Immunology, Department of Microbiology, Faculty of Medicine, Center of Excellence in Immunology and Immune‐Mediated Diseases Chulalongkorn University Bangkok Thailand

Abstract

AbstractDrug causality assessment in severe cutaneous adverse reactions (SCARs) remains challenging. We investigated the usefulness of in‐vivo drug patch tests (PT), ex‐vivo interferon (IFN)‐γ enzyme‐linked immunospot (ELISpot) assay, and lymphocyte transformation test (LTT) in 30 SCARs patients within the past 36 months. Drug PT yielded a 20% positivity rate (n = 6), while IFN‐γ ELISpot and LTT showed positive rates of 56.67% (n = 17) and 41.38% (n = 12), respectively. Combining the three tests resulted in an overall positive rate of 66.67% (n = 20) of cases. IFN‐γ ELISpot offered additional positivity, especially with oxypurinol. Employing a combined diagnostic approach may enhance the chances of obtaining a positive result.

Funder

Health Systems Research Institute

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1346-8138.17207

Reference14 articles.

1. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations

2. Diagnosis and management of drug hypersensitivity reactions

3. In Vitro Assays in Severe Cutaneous Adverse Drug Reactions: Are They Still Research Tools or Diagnostic Tests Already?

4. Analysis of HLA-B Allelic Variation and IFN-γ ELISpot Responses in Patients with Severe Cutaneous Adverse Reactions Associated with Drugs

5. The lymphocyte transformation test in the diagnosis of drug hypersensitivity